Sionna Therapeutics, Inc. Logo

Sionna Therapeutics, Inc.

Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.

SION | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
21 HICKORY DRIVE, SUITE 500, 2451 WALTHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformative treatments for cystic fibrosis (CF). The company's mission is to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Its novel approach centers on stabilizing the protein's nucleotide-binding domain 1 (NBD1), which directly targets the defect caused by F508del, the most common CF-causing mutation. Sionna is advancing a pipeline of proprietary small molecule NBD1 stabilizers, such as SION-719, and a portfolio of complementary CFTR modulators designed to work synergistically. The ultimate goal is to restore CFTR function to near-normal levels, revolutionizing the treatment paradigm for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sionna Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sionna Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sionna Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland
NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland
NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany
NN6
NANOVIRICIDES, INC. Logo
Developing biomimetic nanomachines as broad-spectrum drugs to neutralize viral infections.
United States of America
NNVC
Nasus Pharma Ltd Logo
Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.
United States of America
NSRX
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain
NAT
Natera, Inc. Logo
Provides non-invasive cfDNA tests for oncology, women's health, and organ health.
United States of America
NTRA
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea
168330
Naturland Holding PLC Logo
A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.
United Kingdom
NATUR
NEKTAR THERAPEUTICS Logo
Biopharma developing innovative medicines for autoimmune and inflammatory conditions.
United States of America
NKTR

Talk to a Data Expert

Have a question? We'll get back to you promptly.